Skip to main content
Smart Investors Daily
NV

NASDAQ · NVS

Novartis AG

Healthcare · Drug Manufacturers - General

$151.22

Down-$3.99 (-2.57%)

Updated Nov 20, 2026, 2:03 AM

SID Score

6.4/10

Composite research score

Smart Money

43/100

Neutral

Market cap
258.98B
P/E ratio
18.18
Dividend yield
2.64%
52-week range
$123.24 – $170.46
Volume
3.55M
Avg. volume
1.65M

Price performance · NVS

NVS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

NVS closed at $151.22 after 21 trading sessions, down 3.23% for the selected period.

Last close
$151.22
Period change
-3.23%
Period low
$151.12
Period high
$164.98
Daily close
View OHLC price history
NVS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$151.55$153.18$150.73$151.223.55M
Nov 18, 2026$157.085$157.98$154.81$155.212.77M
Nov 17, 2026$158.46$160.03$158.37$159.131.46M
Nov 16, 2026$162.36$163.275$159.94$160.201.63M
Nov 13, 2026$160.11$160.84$159.48$160.501.42M
Nov 12, 2026$160.98$161.32$159.93$160.252.14M
Nov 11, 2026$159.64$160.68$159.20$160.322.32M
Nov 10, 2026$162.595$164.18$162.36$163.261.98M
Nov 9, 2026$163.73$164.18$161.52$163.692.32M
Nov 6, 2026$159.40$163.11$159.36$162.552M
Nov 5, 2026$163.24$165.96$161.65$161.932.44M
Nov 4, 2026$163.69$165.05$162.16$164.981.74M
Nov 3, 2026$161.305$161.79$158.925$159.261.34M
Nov 2, 2026$160.54$161.87$160.11$161.521.55M
Oct 30, 2026$162.53$164.055$160.40$160.793.15M
Oct 29, 2026$160.68$162.19$159.91$161.102.24M
Oct 28, 2026$154.86$157.41$154.11$156.081.95M
Oct 27, 2026$154.15$156.985$154.13$156.863.73M
Oct 26, 2026$153.525$154.24$152.02$153.812.82M
Oct 23, 2026$156.08$156.08$149.17$151.124.36M
Oct 22, 2026$154.90$157.10$154.38$156.272.08M

Latest NVS news

The latest Smart Investors Daily articles mentioning NVS.

NVS research

Overview

Company profile and research snapshot.

Company profile

Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$127.00
Implied upside
—
Analysts
13
NVS recent ratings
DateFirmRatingTarget
Sep 23, 2026ROTHSCHILD & CO REDBURNSell—
Sep 23, 2026LANDESBANK BADEN-WUERTTEMBERGHold—
Sep 21, 2026BERENBERGHold—
Sep 18, 2026JEFFERIESHold—
Sep 17, 2026BAADER EUROPE / ALPHAVALUEBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 19, 2026

NKT sees 2026 EBITDA at top of guidance despite Q3 profit miss

Investing.com -- Danish cable maker NKT said on Thursday it expects to finish 2026 at the upper end of its EBITDA guidance range, despite third-quarter revenue and core profit falling short of analyst expectations as high-voltage project timing weighed on sales.

AI research layers

Interpretive context generated from the platform’s current data sources.

Novartis AG Stock Performance

Novartis AG shares currently trade at $155.21, reflecting a strong 5.95% gain over the past month and a robust 20.64% appreciation over the trailing twelve months, per SID market data. The stock is trading above both its 50-day moving average of $149.57 and its 200-day moving average of $152.62, indicating sustained upward momentum across multiple timeframes. The 14-day relative strength index stands at 56.4, positioning the stock in neutral territory without overbought or overextended signals. Novartis maintains a notably low beta of 0.438, according to Massive/Polygon data, underscoring its defensive characteristics relative to the broader market. Average daily trading volume registers at approximately 1.65 million shares, supporting adequate liquidity for institutional participants. Despite the monthly strength, the three-month return of negative 0.74% suggests some interim consolidation before the recent rally resumed, contributing to the current market capitalization of approximately $259 billion.

Novartis AG Valuation Analysis

Novartis AG trades at a price-to-earnings ratio of 18.18, positioning it within a moderate valuation range for the Healthcare sector, per SID market data. The company's price-to-book ratio stands at 5.90, reflecting the premium investors assign to its diversified pharmaceutical portfolio and intellectual property assets. The PEG ratio registers at negative 0.79, according to SEC filings, which limits its utility as a growth-adjusted valuation metric and suggests analysts project earnings variability in forward periods. Novartis offers a dividend yield of approximately 3.31%, a meaningful income component that distinguishes it among large-cap pharmaceutical peers and aligns with its historical commitment to shareholder returns. The company's market capitalization of approximately $259 billion places it among the largest global pharmaceutical companies by market value. The combination of a sub-20 P/E ratio with a yield exceeding three percent reflects a valuation profile consistent with mature, cash-generative healthcare enterprises.

Smart Money Activity for NVS

Novartis AG registers a composite smart money score of 43 out of 100 with a neutral overall signal, per SID market data. Institutional activity represents the strongest component at 21.0 out of 25, indicating substantial ongoing engagement from large asset managers and pension funds in their 13F institutional filings. Insider activity scores 12.5 out of 25, reflecting a moderate level of executive and director transactions as documented in SEC Form 4 filings, without a decisive directional bias. Dark pool activity scores 8.5 out of 25, suggesting below-average off-exchange trading volume relative to comparable large-cap healthcare names. Congressional trading activity is minimal at 0.8 out of 25, indicating negligible disclosed positions among U.S. lawmakers. The divergence between strong institutional engagement and weaker dark pool and congressional metrics creates the neutral composite reading. The high institutional score is consistent with Novartis's status as a widely held constituent of major global indices, while the subdued dark pool activity may reflect the stock's lower beta profile reducing short-term tactical positioning interest.

Novartis AG Earnings Outlook

Novartis AG has demonstrated a consistent pattern of exceeding analyst expectations in its most recent reported quarters, according to company earnings reports. In the most recent quarter, the company posted earnings per share of $2.46 against a consensus estimate of $2.24, representing a positive surprise of $0.22. The preceding quarter similarly delivered a beat, with actual EPS of $2.41 versus estimates of $2.16, a $0.25 upside surprise. These consecutive beats reflect strong operational execution and disciplined cost management. Looking ahead, analyst estimates project EPS of $2.13 for the upcoming quarter with results expected on July 16, 2026, and $2.10 for the following quarter scheduled for May 1, 2026, per analyst estimates. The sequential upward trajectory from estimated to actual results suggests analysts may be applying conservative modeling assumptions. The upcoming reporting dates will provide further visibility into whether Novartis can sustain its outperformance pattern.

Wall Street Analyst Ratings for NVS

Recent Wall Street analyst activity on Novartis AG reflects a predominantly cautious consensus, per SID consensus data. In the most recent round of coverage updates, Jefferies maintained a Hold rating on September 18, 2026, while Berenberg and Landesbank Baden-Wuerttemberg both reiterated Hold recommendations on September 21 and September 23, respectively. Rothschild & Co Redburn maintained its Sell rating on September 23, representing the most bearish stance among recent coverage initiators. On the constructive side, Baader Europe/AlphaValue reiterated a Buy rating on September 17, 2026, standing as the sole bullish voice in the latest analyst updates, according to Wall Street analyst reports. The concentration of Hold ratings suggests the analyst community views the stock as fairly valued following its 20.64% one-year appreciation. The absence of price target upgrades accompanying these reiterations indicates limited near-term catalysts identified by the coverage universe, with three of five recent ratings clustering at Hold and the distribution skewing neutral to cautious.